Verdict
MDL 3140 Bellwether Trial (Pending)
Rule 702 hearings on general causation are scheduled for late May 2026. Bellwether trial selection and scheduling will follow. No verdict has been reached yet.
Active litigationUpdated JUL 4, 2026
Depo-Provera (medroxyprogesterone acetate / MPA) is a contraceptive injection given every three months. More than 5,830 lawsuits consolidated in MDL 3140 in the Northern District of Florida allege that Pfizer failed to warn about a significantly elevated risk of meningioma — a tumor in the tissue surrounding the brain and spinal cord. In June 2026, Pfizer reached an agreement in principle to resolve the federal MDL claims, though final terms and compensation amounts have not been disclosed and state-court cases are not covered. Women who received the shot for more than one year face up to a 5.6-fold increased risk, which rises with duration of use.
From the docket
Litigation Timeline
13 ENTRIES
Upjohn Seeks First FDA Approval — Rejected Over Cancer Concerns
Upjohn Company submits a new drug application for Depo-Provera as a contraceptive. The FDA identifies cancer concerns after beagle dogs develop tumors and rejects the application.
FDA Approves U.S. Meningioma Warning After Decade of International Warnings
The FDA approves Pfizer's supplemental label change adding meningioma to Depo-Provera's Warnings and Precautions — a full decade after Canada's 2015 warning. Rule 702 hearings on general causation are set for May 2026.
FDA Rejects Depo-Provera a Second Time
After a seven-year beagle study reveals malignant breast tumors in two of 36 test animals, the FDA again rejects Depo-Provera for contraceptive use in the United States.
FDA Public Board of Inquiry — Third Rejection
A rare FDA Public Board of Inquiry convenes to evaluate Depo-Provera safety. The board recommends against approval, making it the third federal rejection.
FDA Finally Approves Depo-Provera After 25 Years
Despite three prior rejections and opposition from women's health advocates, the FDA approves Depo-Provera as a contraceptive. Upjohn argues that international experience with over 30 million users supports safety.
Pfizer Acquires Pharmacia & Upjohn
Pfizer completes its acquisition of Pharmacia Corporation (which had merged with Upjohn in 1995), inheriting Depo-Provera and all associated regulatory responsibilities and liabilities.
FDA Adds Black Box Warning for Bone Density Loss
The FDA requires its most serious warning — a black box — regarding significant bone mineral density loss with long-term use, recommending a 2-year usage limit.
Canada Adds Meningioma Warning to Depo-Provera Label
Health Canada adds meningioma as an adverse reaction to the Canadian Depo-Provera label, noting reports of meningiomas following long-term progestin administration. American women receive no equivalent warning.
French BMJ Study Reports 5.6x Meningioma Risk
Roland et al. publish a landmark population-based study in The BMJ showing that women who received Depo-Provera long-term face a 5.6-fold increased risk of meningioma. The study triggers a wave of U.S. lawsuits.
MDL 3140 Established in Northern District of Florida
The Judicial Panel on Multidistrict Litigation consolidates all federal Depo-Provera meningioma lawsuits into MDL 3140 under Judge M. Casey Rodgers in the Northern District of Florida.
- July 2026
JAMA Network Open Study Reports 4.5x Meningioma Risk with Medroxyprogesteronescientific
A peer-reviewed study published July 1, 2026 in JAMA Network Open (PMID 42390859) by Hasselblad Lundstrøm N et al. reported a risk ratio of 4.5 for meningioma among users of medroxyprogesterone, a progestogen used in contraceptives including Depo-Provera. The study adds to a growing body of scientific literature examining a possible link between progestogen-based contraceptives and brain tumor development.
- July 2026
JAMA Network Open Study Reports 4.5x Meningioma Risk With Medroxyprogesteronescientific
A peer-reviewed study published July 1, 2026 in JAMA Network Open (PMID 42390859) by Hasselblad Lundstrøm N et al. reported a risk ratio of 4.5 for meningioma among users of the contraceptive progestogen medroxyprogesterone, the active ingredient in Depo-Provera. The study, titled 'Contraceptive Progestogens and Incident Meningioma,' adds to a growing body of scientific literature examining the relationship between progestogen-based contraceptives and brain tumor development.
- June 2026
Pfizer Reaches Agreement in Principle to Resolve Federal Depo-Provera MDLsettlement
On June 15, 2026, U.S. District Judge M. Casey Rodgers entered an order noting that Pfizer had reached an agreement in principle with plaintiffs' leadership in MDL 3140 to resolve the federal Depo-Provera meningioma claims. The agreement is not final, no compensation terms have been disclosed, and Pfizer stated it includes no admission of liability and does not affect cases pending in state courts. The court subsequently vacated upcoming bellwether trial deadlines while the terms are finalized.
Case results
Notable Verdicts & Settlements
5 ON RECORD
Verdict
Comparable: Mirena IUD Pseudotumor Cerebri Litigation
$12.2 million individual verdict in Mirena IUD litigation involving pseudotumor cerebri (elevated intracranial pressure). Bayer faced failure-to-warn claims similar to the Depo-Provera meningioma theory. The neurological injury parallel makes this a key benchmark.
Verdict
Comparable: Depakote Birth Defect — $15M Verdict
$15 million verdict against Abbott Laboratories for failure to warn about Depakote birth defect risks. The pharmaceutical failure-to-warn theory and pregnancy/reproductive health context parallel the Depo-Provera litigation.
Verdict
Comparable: Actos Bladder Cancer — $9B Verdict (Later Reduced)
$9 billion verdict (later reduced to $36.8 million) against Takeda Pharmaceuticals for hiding bladder cancer risks of the diabetes drug Actos. Demonstrates potential for massive jury awards when pharmaceutical companies are found to have concealed known cancer risks.
Verdict
Comparable: NuvaRing Contraceptive Settlement — $100M Total
$100 million global settlement by Merck resolving approximately 3,800 NuvaRing hormonal contraceptive injury claims. As a hormonal birth control failure-to-warn case with a similar plaintiff profile, NuvaRing provides a baseline comparator for per-plaintiff values in the Depo-Provera litigation.
Stay informed
Get free updates on the Depo-Provera Brain Tumor litigation as it develops
No phone call required. We will email you when there is meaningful news — new filings, settlements, or important deadlines.
Full case details
Want the complete picture?
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View the full Depo-Provera Brain Tumor case page →